What Changed This Week in FDA Cancer Approvals: July 21, 2026

Four approvals, four different lessons

In the two weeks up to July 21, 2026, the FDA's oncology approval feed logged four decisions. Read together, they show most of the ways an approval can be narrower than its headline.

July 14 — gedatolisib (Revtorpyk), with fulvestrant. For adults with advanced or metastatic breast cancer that is hormone receptor-positive and HER2-negative. The tumor must not carry a PIK3CA mutation. The cancer must have grown after at least one round of endocrine therapy.

July 14 — selpercatinib (Retevmo). This one moved from accelerated to traditional approval. It is for adults and children aged two and over. The tumor can start anywhere, but it must carry a RET gene fusion, found by an FDA-approved test, and must have grown after earlier treatment.

July 10 — pembrolizumab (Keytruda) with enfortumab vedotin (Padcev). For adults with muscle-invasive bladder cancer, given before surgery and again after the bladder is removed. The FDA widened an approval it had already granted. It used to cover only patients who could not take cisplatin. It now covers everyone who is a candidate for the operation.

July 9 — isatuximab (Sarclisa Escena). Approved as an injection under the skin, for multiple myeloma.

The four things a label controls

Cancer type is not enough. The breast cancer approval covers one receptor pattern, in one setting, after one kind of prior treatment. Someone with early-stage breast cancer is not in that group. Nor is someone with triple-negative disease.

A biomarker can be required, or required to be absent. Selpercatinib needs a RET fusion. Gedatolisib needs the absence of a PIK3CA mutation. Either way, a lab result comes first. Our page on biomarker testing and precision medicine explains how those tests are ordered.

Where in the sequence matters. The bladder approval covers neoadjuvant treatment, meaning before surgery, and adjuvant treatment, meaning after. That is a different question from treatment for cancer that has already spread.

Accelerated is not the same as traditional. Selpercatinib's move to traditional approval means the confirming evidence arrived. Accelerated approval rests on an earlier signal, usually tumor shrinkage. Proof of real benefit is still owed. The FDA keeps a public list of cancer accelerated approvals that are still waiting on it.

The medicine behind the bladder approval

Muscle-invasive bladder cancer is the clearest example of why sequencing matters, so it is worth following through.

The bladder wall has a muscle layer. A cancer that has not reached it is called non-muscle-invasive. That kind can often be removed through the urethra with a scope.

Once the cancer invades the muscle, the standard operation is a radical cystectomy. The surgeon takes out the bladder, nearby lymph nodes, and any neighboring organ containing cancer. Then comes a urinary diversion, a new route for urine to leave the body.

Drug treatment before that operation aims to shrink the tumor and kill cells that have already escaped. Drug treatment afterward aims to clear what surgery could not reach.

The 2026 count is an American Cancer Society projection carried by SEER: 84,530 new US bladder cancer cases and 17,870 deaths. NCI's registry adds the measured detail — a median age at diagnosis of 73, and five-year relative survival, for people diagnosed between 2016 and 2022, of 98.0% while the cancer is still in the layer where it started, 73.0% once confined to the bladder proper, 41.8% once it reaches nearby lymph nodes, and 9.6% once it has spread further. Those are group averages, not predictions.

Multiple myeloma has a different shape. ACS estimates 36,000 new US cases and 10,850 deaths for 2026, again republished by SEER. Five-year relative survival, from NCI's data on people diagnosed between 2016 and 2022, is 63.7%. Ninety-six percent are counted as distant at diagnosis. That is not a sign of late detection. Myeloma is a blood cancer, and it sits in the marrow throughout the body from the start.

So the change from a drip to an injection is not cosmetic. It replaces hours in an infusion chair, for a disease treated over years.

When to get checked

For the cancers in this week's list, these are the symptoms that warrant an appointment:

• Bladder: blood in the urine, even once, even if it does not come back
• Bladder: needing to urinate often or urgently, or pain when you do
• Breast: a new lump or thickened area, or skin that has dimpled or reddened
• Breast: a nipple turning inward, or new discharge from one side
• Myeloma: bone pain that lasts, above all in the back or ribs
• Myeloma: a fracture with no real injury, or infections that keep coming back
• Any: weight loss with no known cause, or fatigue that rest does not lift

Blood in the urine in an adult deserves an appointment the same week, whatever the amount.

What this does not mean

• None of these approvals is a general advance for everyone with the named cancer. Each defines a narrow group.
• A biomarker requirement means the drug is not an option without the test result, whatever the cancer type.
• Widening an approval, as with the bladder regimen, does not make it right for every patient it now covers.
• Accelerated approval means confirmatory evidence is still owed. It is not evidence that people live longer.
• Nothing here is a reason to start, stop or change a treatment. Only a care team can read a label against a specific case.

Sources

• FDA, Oncology (Cancer) / Hematologic Malignancies Approval Notifications — https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications
• FDA, Ongoing Cancer Accelerated Approvals — https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
• NCI PDQ, Bladder Cancer Treatment (Patient Version) — https://www.cancer.gov/types/bladder/patient/bladder-treatment-pdq
• NCI, Symptoms of Bladder Cancer — https://www.cancer.gov/types/bladder/symptoms
• SEER Cancer Stat Facts, Bladder Cancer — https://seer.cancer.gov/statfacts/html/urinb.html
• SEER Cancer Stat Facts, Myeloma — https://seer.cancer.gov/statfacts/html/mulmy.html

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.